• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4640408)   Today's Articles (203)   Subscriber (50362)
For: Verstovsek S, Silver RT, Cross NCP, Tefferi A. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia 2006;20:2067. [PMID: 16990780 DOI: 10.1038/sj.leu.2404379] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Number Cited by Other Article(s)
1
Reza MT, Alam MGR, Rahman R, Dipto SM. Domain affiliated distilled knowledge transfer for improved convergence of Ph-negative MPN identifier. PLoS One 2024;19:e0303541. [PMID: 39331624 PMCID: PMC11433141 DOI: 10.1371/journal.pone.0303541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Accepted: 04/26/2024] [Indexed: 09/29/2024]  Open
2
Mustafa AHM, Krämer OH. Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. Pharmacol Rev 2023;75:35-61. [PMID: 36752816 DOI: 10.1124/pharmrev.122.000612] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 07/08/2022] [Accepted: 08/15/2022] [Indexed: 12/13/2022]  Open
3
Murphy AJ, Dragoljevic D, Natarajan P, Wang N. Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk. Thromb Haemost 2022;122:1435-1442. [PMID: 35445383 PMCID: PMC9420552 DOI: 10.1055/a-1830-2147] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Accepted: 02/23/2022] [Indexed: 11/28/2022]
4
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs. Blood Adv 2021;4:4554-4559. [PMID: 32956452 DOI: 10.1182/bloodadvances.2019001283] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Accepted: 08/21/2020] [Indexed: 12/12/2022]  Open
5
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia 2021;35:2592-2601. [PMID: 33654206 DOI: 10.1038/s41375-021-01183-8] [Citation(s) in RCA: 53] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 01/15/2021] [Accepted: 02/02/2021] [Indexed: 01/12/2023]
6
La Rocca F, Grieco V, Ruggieri V, Zifarone E, Villani O, Zoppoli P, Russi S, Laurino S, Falco G, Calice G, Marinaccio A, Natalicchio MI, Albano F, Musto P. Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for JAK2 V617F Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study. Diagnostics (Basel) 2020;10:diagnostics10030143. [PMID: 32150880 PMCID: PMC7151190 DOI: 10.3390/diagnostics10030143] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Revised: 03/02/2020] [Accepted: 03/03/2020] [Indexed: 12/11/2022]  Open
7
Yoo EH, Park KJ, Won HH, Park JH, Park JH, Lee ST, Kim HJ, Bang SM, Chi HS, Jung CW, Kim SH, Yun H, Sun CH, Park I, Lee S, Lee C, Merriman B, Luo R, Tan EHH, Park KJ, Yoo NK, Kang JJ, Kim JW. Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients. J Clin Lab Anal 2016;30:1061-1070. [PMID: 27132877 DOI: 10.1002/jcla.21981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Accepted: 03/09/2016] [Indexed: 11/11/2022]  Open
8
Saeidi K. Myeloproliferative neoplasms: Current molecular biology and genetics. Crit Rev Oncol Hematol 2015;98:375-89. [PMID: 26697989 DOI: 10.1016/j.critrevonc.2015.11.004] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2015] [Revised: 09/10/2015] [Accepted: 11/09/2015] [Indexed: 12/16/2022]  Open
9
Patnaik MM, Tefferi A. Molecular diagnosis of myeloproliferative neoplasms. Expert Rev Mol Diagn 2014;9:481-92. [DOI: 10.1586/erm.09.29] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
10
Percy MJ. Genetically heterogeneous origins of idiopathic erythrocytosis. Hematology 2013;12:131-9. [PMID: 17454194 DOI: 10.1080/10245330601111979] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]  Open
11
Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013;122:1881-6. [PMID: 23900239 DOI: 10.1182/blood-2013-06-508416] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]  Open
12
Barcelos MM, Santos-Silva MC. Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter 2012;33:290-6. [PMID: 23049320 PMCID: PMC3415756 DOI: 10.5581/1516-8484.20110079] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2010] [Accepted: 04/01/2011] [Indexed: 01/01/2023]  Open
13
Wu Z, Yuan H, Zhang X, Liu W, Xu J, Zhang W, Guan M. Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. PLoS One 2011;6:e26534. [PMID: 22028900 PMCID: PMC3197667 DOI: 10.1371/journal.pone.0026534] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2011] [Accepted: 09/28/2011] [Indexed: 11/18/2022]  Open
14
Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011;86:668-76. [PMID: 21674578 DOI: 10.1002/ajh.22063] [Citation(s) in RCA: 110] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2011] [Revised: 04/13/2011] [Accepted: 04/15/2011] [Indexed: 12/12/2022]
15
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics 2011;2:197-212. [PMID: 22704337 PMCID: PMC3365400 DOI: 10.1007/s13148-011-0050-6] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2011] [Accepted: 06/29/2011] [Indexed: 12/13/2022]  Open
16
BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2011;11 Suppl 1:S37-45. [PMID: 22035746 DOI: 10.1016/j.clml.2011.04.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/19/2011] [Revised: 04/07/2011] [Accepted: 04/07/2011] [Indexed: 01/12/2023]
17
Means RT. JAK2 V617F and the evolving paradigm of polycythemia vera. THE KOREAN JOURNAL OF HEMATOLOGY 2010;45:90-4. [PMID: 21120186 PMCID: PMC2983020 DOI: 10.5045/kjh.2010.45.2.90] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/24/2010] [Revised: 06/18/2010] [Accepted: 06/21/2010] [Indexed: 01/04/2023]
18
Patnaik MM, Knudson RA, Gangat N, Hanson CA, Pardanani A, Tefferi A, Ketterling RP. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. Eur J Haematol 2010;84:518-24. [DOI: 10.1111/j.1600-0609.2010.01428.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
19
Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 2010;91:174-9. [PMID: 20191332 DOI: 10.1007/s12185-010-0529-5] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2009] [Accepted: 02/07/2010] [Indexed: 01/21/2023]
20
Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn 2009;12:58-64. [PMID: 19959796 DOI: 10.2353/jmoldx.2010.090068] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]  Open
21
Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009;60:233-45. [PMID: 18947294 DOI: 10.1146/annurev.med.60.041707.160528] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
22
Vannucchi AM, Guglielmelli P, Rambaldi A, Bogani C, Barbui T. Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med 2009;13:1437-50. [PMID: 19522842 PMCID: PMC3828857 DOI: 10.1111/j.1582-4934.2009.00827.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2009] [Accepted: 06/03/2009] [Indexed: 12/18/2022]  Open
23
Nussenzveig RH, Cortes J, Sever M, Quintás-Cardama A, Ault P, Manshouri T, Bueso-Ramos C, Prchal JT, Kantarjian H, Verstovsek S. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol 2009;90:58-63. [PMID: 19484334 DOI: 10.1007/s12185-009-0345-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2009] [Revised: 04/27/2009] [Accepted: 05/07/2009] [Indexed: 10/20/2022]
24
Tefferi A, Levine RL, Kantarjian H. Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms. Biol Blood Marrow Transplant 2009;15:114-9. [DOI: 10.1016/j.bbmt.2008.10.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
25
Tefferi A. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med 2008;13:215-37. [PMID: 19175693 PMCID: PMC3823350 DOI: 10.1111/j.1582-4934.2008.00559.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]  Open
26
JAK2 V617F Mutation Testing in Polycythemia Vera: Use and Impact in an Academic Practice. Am J Med Sci 2008;336:327-9. [DOI: 10.1097/maj.0b013e3181695687] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
27
Perspective: Osler's 1903 paper on polycythemia vera. Am J Med Sci 2008;335:418-9. [PMID: 18552569 DOI: 10.1097/maj.0b013e318175d14e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
28
Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008;83:491-7. [PMID: 18429051 DOI: 10.1002/ajh.21183] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
29
Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008;49:388-97. [PMID: 18297515 DOI: 10.1080/10428190801895360] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
30
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008;22:708-22. [PMID: 18337766 DOI: 10.1038/leu.2008.27] [Citation(s) in RCA: 184] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
31
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008;22:686-707. [DOI: 10.1038/leu.2008.26] [Citation(s) in RCA: 293] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
32
JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 2008;13:366-71. [PMID: 18032973 DOI: 10.1097/ppo.0b013e318159467b] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
33
Ohyashiki K, Hori K, Makino T, Ohyashiki JH. Automated JAK2V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection. ACTA ACUST UNITED AC 2008;179:19-24. [PMID: 17981210 DOI: 10.1016/j.cancergencyto.2007.07.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2007] [Accepted: 07/13/2007] [Indexed: 10/22/2022]
34
Wang YL, Vandris K, Jones A, Cross NCP, Christos P, Adriano F, Silver RT. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia 2007;22:1289. [PMID: 18079740 DOI: 10.1038/sj.leu.2405047] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
35
Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia 2007;22:3-13. [PMID: 17882283 DOI: 10.1038/sj.leu.2404946] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
36
Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2007;22:14-22. [PMID: 17882280 DOI: 10.1038/sj.leu.2404955] [Citation(s) in RCA: 766] [Impact Index Per Article: 45.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
37
Pardanani A, Lasho TL, Finke C, Markovic SN, Tefferi A. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia 2007;21:2206-7. [PMID: 17507998 DOI: 10.1038/sj.leu.2404749] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
38
Tefferi A, Vardiman JW. The diagnostic interface between histology and molecular tests in myeloproliferative disorders. Curr Opin Hematol 2007;14:115-22. [PMID: 17255788 DOI: 10.1097/moh.0b013e32801684d9] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
39
Ohyashiki K, Aota Y, Akahane D, Gotoh A, Ohyashiki JH. JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 2007;21:1097-9. [PMID: 17315023 DOI: 10.1038/sj.leu.2404604] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
40
Tefferi A. Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era. Hematology 2006:240-5. [PMID: 17124067 DOI: 10.1182/asheducation-2006.1.240] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA